Department of Psychiatry and Psychotherapy, University Hospital Munich, Nußbaumstraße 7, 80336 München, Germany.
Department of Psychiatry and Psychotherapy, University Hospital Munich, Nußbaumstraße 7, 80336 München, Germany.
Schizophr Res. 2020 Aug;222:73-78. doi: 10.1016/j.schres.2020.05.028. Epub 2020 Jun 26.
Catatonia is a potentially life threatening syndrome in various psychiatric disorders. As first line treatment, benzodiazepines and electroconvulsive therapy (ECT) are recommended. In some cases, benzodiazepines are ineffective and ECT is not available or contraindicated. Therefore, the search for new and alternative treatment strategies is of great importance.
To review the evidence for alternative neurostimulation treatment strategies (rTMS and tDCS) for catatonia according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines.
We performed a systematic literature search in several electronic databases. We also searched the WHO International Clinical Trials Registry Platform (ICTRP) and the ClinicalTrials.gov database to detect registered studies.
We identified nine publications on rTMS treatment and four publications on tDCS in catatonia. Most of the publications reported clinically relevant improvement of catatonic symptoms. Only two publications reported insufficient improvement. The available Bush-Francis Catatonia Rating Scale scores showed statistical significant improvement following rTMS and tDCS. We could not identify any finished clinical studies or case series, dedicated to this topic. We also could not identify any publications that compared first line treatment options with rTMS or tDCS.
Based on the case report literature, rTMS and tDCS might be promising alternative treatment strategies for patients who do not respond to benzodiazepines or in case ECT is not available or contraindicated. There are even hints that rTMS or tDCS might be an option in patients who respond to ECT but need long-term treatment to control catatonic symptoms. Further clinical trials are needed to allow for an evidence-based evaluation of potential risks and benefits of rTMS and tDCS for catatonia.
在各种精神障碍中,紧张症是一种潜在危及生命的综合征。作为一线治疗方法,推荐使用苯二氮䓬类药物和电惊厥疗法(ECT)。在某些情况下,苯二氮䓬类药物无效,且 ECT 不可用或禁忌。因此,寻找新的和替代的治疗策略非常重要。
根据系统评价和荟萃分析的首选报告项目(PRISMA)指南,综述替代神经刺激治疗紧张症的证据(rTMS 和 tDCS)。
我们在多个电子数据库中进行了系统文献检索。我们还在世界卫生组织国际临床试验注册平台(ICTRP)和 ClinicalTrials.gov 数据库中进行了检索,以检测已注册的研究。
我们确定了 9 篇关于 rTMS 治疗紧张症和 4 篇关于 tDCS 治疗紧张症的出版物。大多数出版物报告了紧张症症状的临床相关改善。只有 2 篇出版物报告了改善不足。可用的 Bush-Francis 紧张症评定量表评分表明,rTMS 和 tDCS 后有统计学显著改善。我们没有发现任何专门针对这一主题的完成的临床研究或病例系列。我们也没有发现任何将一线治疗选择与 rTMS 或 tDCS 进行比较的出版物。
基于病例报告文献,rTMS 和 tDCS 可能是对苯二氮䓬类药物无反应或 ECT 不可用或禁忌的患者的有前途的替代治疗策略。甚至有迹象表明,rTMS 或 tDCS 可能是对 ECT 有反应但需要长期治疗以控制紧张症症状的患者的一种选择。需要进一步的临床试验,以便对 rTMS 和 tDCS 治疗紧张症的潜在风险和益处进行基于证据的评估。